Jade Biosciences Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
HC Wainwright & Co. has reiterated its Buy rating for Jade Biosciences (OTCQB:JADE) and maintained a price target of $55.00 per share. This indicates continued confidence from the firm in the company's future performance.
Analysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Liquidia Technologies (LQDA)
Two healthcare stocks, Jade Biosciences (JBIO) and Liquidia Technologies (LQDA), have received bullish ratings from analysts. Jade Biosciences was reiterated with a Buy rating and has a "Strong Buy" consensus with significant upside potential. Liquidia Technologies also maintained a Buy rating and holds a "Moderate Buy" consensus.
Stifel reiterates Jade Biosciences stock rating on drug data
Stifel reiterated a Buy rating and a $40.00 price target for Jade Biosciences (NASDAQ:JBIO) following new preclinical data for its drug candidate JADE301. JADE301, an anti-IFN-β monoclonal antibody, is being developed for Dermatomyositis and shows improved affinity, potency, and half-life compared to existing treatments. Jade Biosciences plans to start a Phase 1 trial in Q4 2026, with interim results expected in H2 2027, aiming to achieve better dosing and potentially expand indications to other IFN-β driven diseases.
Stifel reiterates Jade Biosciences stock rating on drug data By Investing.com
Stifel maintained its Buy rating and $40 price target for Jade Biosciences (NASDAQ:JBIO) after the company presented preclinical data for JADE301, a drug for Dermatomyositis. JADE301, an anti-IFN-β monoclonal antibody, is designed to improve upon existing treatments with higher potency and a longer half-life, with a Phase 1 trial expected in Q4 2026. This positive outlook is further supported by recent developments for other Jade Biosciences' drugs, including a price target increase from Wedbush and validation of JADE101 for IgA nephropathy.
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Jade Biosciences announced preclinical data for JADE301, an anti-IFN-β monoclonal antibody for dermatomyositis, highlighting its high-affinity binding, greater functional potency, and extended half-life compared to a comparator. The company plans to initiate a Phase 1 healthy volunteer trial in Q4 2026, with interim data expected in H2 2027. JADE301 is designed for infrequent subcutaneous dosing to provide durable improvement for patients.
Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
Jade Biosciences has announced preclinical data for Jade301, a novel half-life-extended anti-IFN-β monoclonal antibody. This drug is being developed for dermatomyositis and is positioned as a potentially best-in-class treatment. The data was presented at EADV 2026.
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Jade Biosciences has announced preclinical data for JADE301, a novel anti-IFN-β monoclonal antibody for dermatomyositis, presented at EADV 2026. The data highlight JADE301's high affinity, potent IFN-β neutralization, extended half-life, and favorable tolerability, suggesting its potential for infrequent subcutaneous dosing. A Phase 1 trial in healthy volunteers is expected to begin in Q4 2026.
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Jade Biosciences announced preclinical data for JADE301, a half-life-extended anti-IFN-β monoclonal antibody developed for dermatomyositis, at EADV 2026. The data show JADE301's high-affinity, selective IFN-β binding, greater functional potency than a comparator, and an extended half-life with predictable distribution into muscle in non-human primates. A Phase 1 healthy volunteer trial is expected to begin in Q4 2026, with interim data anticipated in H2 2027.
Jade Biosciences reports preclinical data for dermatomyositis drug
Jade Biosciences announced promising preclinical data for JADE301, an anti-interferon beta monoclonal antibody being developed for dermatomyositis. The data, presented at the 2026 European Academy of Dermatology and Venereology Congress, demonstrated JADE301's strong binding and inhibition of IFN-β signaling, along with a favorable safety profile in non-human primates. The company plans to initiate a Phase 1 trial in healthy volunteers in Q4 2026, with interim data expected in the second half of 2027.
Jade Biosciences at Stifel 2026 Virtual Immunology and Inflammation Forum: Pipeline Push
Jade Biosciences presented its clinical strategy at the Stifel 2026 Virtual Immunology and Inflammation Forum, focusing on three licensed autoimmune programs. The company highlighted encouraging biomarker data for its lead IgAN candidate, JADE101, which aims for deeper and earlier proteinuria reduction with a convenient quarterly dosing schedule. Despite a recent stock drop, management emphasized the company's strong financial position and ongoing progress in its pipeline, including JADE201 for B-cell mediated autoimmune diseases and JADE301 for dermatomyositis, with data and study initiations planned for 2027 and late 2024 respectively.
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101
Jade Biosciences (JBIO) outlined its three-drug strategy for autoimmune diseases at the Wells Fargo 21st Annual Healthcare Conference, focusing on its lead IgA nephropathy candidate, JADE 101. The company highlighted strong early biomarker data for JADE 101, showing a significant reduction in serum IgA, and confirmed a cash runway into Q4 2028 to fund all three programs. Management also discussed its competitive positioning, pipeline expansion with JADE 201 and JADE 301, and its focus on selective APRIL inhibition for better efficacy and safety.
Clear Street Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48
Clear Street has reiterated its Buy rating for Jade Biosciences (JBIO.US) and increased the target price to $48. This indicates continued confidence in the company's performance and future prospects from the analytical firm.
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences announced its participation in four upcoming healthcare and biopharma conferences in September 2026: the Wells Fargo, Citi, H.C. Wainwright, and Stifel forums. Management will host one-on-one investor meetings, and webcasts of the first three fireside chats will be available on the company's website. The company is a clinical-stage biotechnology firm developing therapies for autoimmune diseases.
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences announced its participation in four upcoming healthcare and investment conferences in September 2026. Management will host one-on-one investor meetings, and webcasts of some fireside chats will be available on the company's website. Jade Biosciences is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases.
Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027
Jade Biosciences is progressing JADE101, a selective APRIL inhibitor for IgA nephropathy (IgAN), with encouraging Phase 1 results showing a significant reduction in IgA levels and a good safety profile. The company aims for quarterly dosing to improve patient adherence compared to competitors. Key interim results from the Phase 2 JUNIPER trial are anticipated in 2027.
Jade Biosciences Company Profile & Introduction
This document is intended to be a company profile and introduction for Jade Biosciences. The content is currently empty, suggesting it will provide foundational information about the company.
Jade Biosciences (JBIO) Stock Analysis Report | Financials & Insights
This report provides a financial analysis of Jade Biosciences (JBIO), a clinical-stage biotechnology company. It covers stock performance, future growth potential based on analyst ratings, and past performance metrics like the Sharpe ratio. The company is focused on developing therapies for autoimmune diseases with its flagship candidate, JADE101, currently in Phase 1 clinical trials.
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55
H.C. Wainwright has reiterated its Buy rating for Jade Biosciences (JBIO.US), keeping the target price at $55. This indicates continued confidence in the company's performance and future prospects from the analyst firm.
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?
Jade Biosciences (JBIO) recently released its Q2 2026 results, reporting a net loss of $55.77 million. Despite strong year-to-date share price returns of 63.91% and a 1-year total shareholder return of 216.64%, the stock's 90-day return declined, and it trades well below the average analyst target. The company remains unprofitable, with a Price-to-Book ratio of 3.4x, which is considered overvalued compared to industry peers.
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?
Jade Biosciences (JBIO) recently reported a Q2 2026 net loss of $55.77 million and a basic loss per share of $0.76. Despite strong year-to-date and one-year shareholder returns of 63.91% and 216.64% respectively, the stock has pulled back 3.81% over 90 days and trades at $23.21, significantly below the average analyst target of $50.13. The company's price-to-book ratio of 3.4x is considered overvalued compared to industry peers, reflecting expectations for its drug pipeline rather than current financial performance, as it remains unprofitable with no reported revenue.
Jade Biosciences Is Maintained at Buy by BTIG
BTIG has reiterated its "Buy" rating for Jade Biosciences. This indicates continued confidence from the firm in the company's stock performance.
Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research
BTIG Research has increased its price target for Jade Biosciences (NASDAQ:JBIO) to $77.00 from $74.00, reiterating a "buy" rating with a potential upside of 254.35%. Despite this, the company reported a quarterly loss of $0.76 per share, missing consensus estimates, and analysts anticipate a full-year loss of $2.54 per share. Institutional investors have recently adjusted their holdings in JBIO, which is a clinical-stage biotechnology company focused on inflammatory skin diseases.
Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside
Analysts have raised the average 12-month price target for Jade Biosciences, Inc. (JBIO) stock from $45.89 to $46.44, with individual forecasts ranging from $25 to $77 per share. This new target suggests a potential upside of approximately 111% from the Aug. 7 closing price. The consensus rating among 11 analysts remains a "Buy," with no "Holds" or "Sells."
Jade Biosciences Releases Q2 2026 Financial Results
Jade Biosciences, Inc. reported a Q2 2026 loss per share of $0.76 and a net loss of $55.8M, reflecting ongoing investment in its biotech development pipeline. The company showed an 11.6% improvement in its per-share loss compared to the prior year. Despite the losses, Wall Street analysts hold a positive outlook, with 8 buy ratings and 1 hold rating.
Wedbush raises Jade Biosciences price target on pipeline progress
Wedbush has increased its price target for Jade Biosciences (NASDAQ:JBIO) to $47 from $45, maintaining an Outperform rating due to consistent pipeline progress. The firm highlighted positive data for JADE101 in IgAN patients and announced a new program, JADE301, targeting dermatomyositis, expected to enter clinical trials in Q4 2026. This positive outlook follows a significant stock increase and recent financial activities, including a successful public offering and new analyst coverage.
Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth
Jade Biosciences, Inc. has filed its quarterly report for Q2 2026, revealing a net loss of $96.1 million for the first half of the year. The company's total assets stood at $472.1 million as of June 30, 2026. The financial results highlight increased research and development efforts and overall asset growth.
Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen
Jade Biosciences reported Q2 EPS of $(0.76), missing the analyst estimate of $(0.64) by 18.75%. This result indicates a widening of operational deficits, with a 11.63% increase in losses compared to the prior year's $(0.86) per share loss. The company's financial performance highlights challenges in cost management or revenue generation, raising investor concerns about near-term profitability.
Jade Biosciences reports $55.8 million Q2 net loss
Jade Biosciences (JBIO) reported a Q2 2026 net loss of $55.8 million, an increase from $32.1 million a year prior. Despite the loss, the company holds $461.2 million in cash and expects its runway to extend into Q4 2028. The biotechnology firm provided updates on its clinical trials, including Phase 2 testing for JADE101, a Phase 1 trial for JADE201, and the introduction of JADE301, alongside a recent $172.5 million public offering.
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences announced its second quarter 2026 financial results and provided a corporate update, highlighting positive interim Phase 1 results for JADE101 in IgA nephropathy and the initiation of a Phase 2 trial. The company also reported progress in its pipeline with JADE201 for rheumatoid arthritis and JADE301 for dermatomyositis, anticipating further clinical trial initiations and data readouts in 2027. Jade Biosciences finished the quarter with $461.2 million in cash, cash equivalents, and investments, projected to fund operations into the fourth quarter of 2028.
Jade Biosciences reports Q2 net loss $55.8M, cash $461.2M; advances JADE101 to Phase 2/3
Jade Biosciences reported a Q2 2026 net loss of $55.8 million, with $461.2 million in cash, cash equivalents, and investments, providing a financial runway into Q4 2028. The company highlighted positive interim Phase 1 results for JADE101, which is advancing to Phase 2/3 trials for IgA nephropathy, and progressed other clinical programs including JADE201 and JADE301. R&D expenses increased to $50.1 million, reflecting heightened clinical and CMC activities.
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences announced its second-quarter 2026 financial results and provided a corporate update, highlighting positive interim Phase 1 results for JADE101 for IgA nephropathy, with a Phase 2 trial underway and a Phase 3 trial expected to begin in early 2027. The company also initiated dosing for JADE201 in rheumatoid arthritis and unveiled JADE301 for dermatomyositis, with a Phase 1 trial planned for Q4 2026. Jade Biosciences reported $461 million in cash, cash equivalents, and investments as of June 30, 2026, projected to fund operations into Q4 2028.
Jade Biosciences Inc expected to post a loss of 64 cents a share - Earnings Preview
Jade Biosciences Inc (JBIO) is projected to report a loss of 64 cents per share. This information comes from a Reuters earnings preview available on TradingView, with further details behind a paywall requiring unlimited access to news sources.
Jade Biosciences (Nasdaq:JBIO) - Stock Analysis
Jade Biosciences (Nasdaq:JBIO) is a biotechnology company developing therapies for autoimmune diseases, primarily focusing on JADE101 for IgA nephropathy. The company has a market cap of US$1.3 billion but is currently unprofitable and its earnings are forecasted to decline. Recent news highlights include positive Phase 1 results for JADE101, its advancement into Phase 2, a $150 million equity offering, and new executive appointments.
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Jade Biosciences, Inc. (JBIO) is highlighted as a promising biotech opportunity in the $20 billion IgA nephropathy market, with UBS initiating coverage with a Buy rating and a $45 price target for its lead program, JADE101. The company announced positive interim Phase 1 study findings for JADE101, showing significant IgA level reductions and a favorable safety profile, with plans to advance to Phase 2 and Phase 3 trials. Despite this potential, the article suggests that certain AI stocks may offer greater upside and less risk.
If You Invested $1,000 in Aerovate Therapeutics, Inc. (AVTE)
This article analyzes the historical performance of a $1,000 investment in Aerovate Therapeutics, Inc. (AVTE), a clinical-stage biopharmaceutical company. It details the company's focus on developing drugs for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) with its lead candidate AV-101. The article also covers the recent strategic review and proposed merger with Jade Biosciences, Inc. following disappointing Phase 2b trial results for AV-101.
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jade Biosciences has appointed Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026. Dr. Eisner brings over 25 years of leadership in clinical development and immunology, with previous roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen, and Genentech/Roche. His expertise is expected to be invaluable as Jade Biosciences advances its pipeline of therapies for autoimmune diseases.
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jade Biosciences announced the appointment of Dr. Mark Eisner to its Board of Directors, effective June 25, 2026. Dr. Eisner brings over 25 years of leadership in clinical development and immunology, with a strong background in guiding innovative therapies from early clinical development through commercialization. This appointment is expected to significantly benefit Jade Biosciences as it advances its pipeline of antibody-based therapies for autoimmune diseases.
Aerovate Therapeutics Inc (AVTE) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Aerovate Therapeutics Inc (AVTE), including its current stock price and market capitalization. It notes that key valuation metrics such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The analysis is presented by TradingKey, which emphasizes that investment decisions should be made with caution as the information is general and not financial advice.
Aerovate Therapeutics Inc (AVTE) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of Aerovate Therapeutics Inc's (AVTE) shareholder structure, detailing major shareholders by proportion and type. It also includes institutional shareholding trends over several quarters, highlighting changes in shares held and ownership percentages, and lists related ETFs that include AVTE.
Aerovate Therapeutics Inc (AVTE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Aerovate Therapeutics Inc (AVTE) stock information, focusing on its dividend and stock split history. It indicates that the company has not distributed dividends in the past five years and has no recorded stock split events. The article also provides current stock quotes and market capitalization for AVTE.
Aerovate Therapeutics Inc (AVTE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses Aerovate Therapeutics Inc (AVTE) revenue breakdown, but states that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It indicates that the company's financial information in these specific categories is currently unavailable. The page gives general stock information like market cap but lacks the detailed revenue segmentation expected from the title.
Aerovate Therapeutics Inc (AVTE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Aerovate Therapeutics Inc (AVTE), including its support and resistance levels, various technical indicators, and moving averages. According to the analysis, the overall signal for AVTE is a "Buy" based on moving averages, with a mix of buy and sell signals from individual indicators. The piece also includes FAQs explaining technical ratings and moving averages for better understanding.
Aerovate Therapeutics Inc (AVTE) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Aerovate Therapeutics Inc (AVTE), focusing on various financial metrics. It includes data points for volatility, maximum drawdown, return-to-drawdown ratio, skewness, and liquidity over different timeframes. However, most of the specific numerical values for these risk indicators are not provided in the current snapshot.
Aerovate Therapeutics Inc (AVTE) Institutional Confidence
This article from TradingKey provides an overview of institutional confidence in Aerovate Therapeutics Inc (AVTE). It lists major institutional shareholders including Fidelity Management & Research Company LLC, Fairmount Funds Management LLC, and RA Capital Management, LP, along with their shareholdings and recent changes. The stock closed at 2.680 USD with a market cap of 77.68M.
Jade Biosciences closes $172.5 million stock offering
Jade Biosciences Inc. successfully completed a public offering, raising $172.5 million through the sale of 11,500,000 shares at $15.00 each. The biotechnology company, which focuses on autoimmune disease therapies, plans to use the proceeds to fund clinical trials, research and development, and general corporate purposes. This follows recent positive Phase 1 trial results for its lead candidate, JADE101, leading analysts to raise price targets for the stock.
Jade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease Therapies
Jade Biosciences successfully completed a public offering of 11.5 million shares at $15.00 per share, raising $172.5 million before expenses. The proceeds, including those from the full exercise of the underwriters' overallotment option, will be used to fund clinical trials, preclinical studies, and manufacturing for its autoimmune disease therapies, such as the lead candidate JADE101. The offering was managed by Jefferies, TD Cowen, UBS Investment Bank, and LifeSci Capital.
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jade Biosciences announced the closing of its public offering of 11,500,000 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of $172.5 million, with shares sold at $15.00 each. The company plans to use the net proceeds to fund clinical trials, preclinical studies, manufacturing, and other general corporate purposes.
Latham & Watkins Advises Jade Biosciences on Public Offering of Common Stock
Latham & Watkins LLP advised Jade Biosciences, Inc. on its public offering of 10,000,000 shares of common stock at US$15.00 per share, expecting to raise gross proceeds of US$150 million. The offering is anticipated to close on June 5, 2026, with underwriters having a 30-day option to purchase an additional 1,500,000 shares. A corporate team from Latham, led by partners Cheston Larson and Matt Bush, represented Jade Biosciences in the transaction.
Jade Biosciences, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Jade Biosciences, Inc., a clinical-stage biotechnology company, announced a proposed underwritten public offering of its common stock or pre-funded warrants. The company intends to use the net proceeds, along with existing funds, to finance clinical trials, preclinical studies, manufacturing, and other research and development activities. Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers for the offering, which is subject to market conditions.
Jade Biosciences Announces Proposed Underwritten Public Offering
Jade Biosciences, a clinical-stage biotechnology company, announced its intention to offer shares of common stock or pre-funded warrants in an underwritten public offering. The company plans to use the net proceeds, along with existing funds, to advance clinical trials, preclinical studies, and manufacturing for its programs, as well as for general corporate purposes. Jefferies, TD Cowen, UBS Investment Bank, LifeSci Capital, and BTIG are managing the offering.
